NGM 282

Drug Profile

NGM 282

Alternative Names: NGM-282

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antihyperglycaemics; Hepatoprotectants; Recombinant proteins
  • Mechanism of Action Cholesterol 7 alpha hydroxylase inhibitors; Fibroblast growth factor receptor modulators; Type 1 fibroblast growth factor receptor modulators; Type 4 fibroblast growth factor receptor modulators; Type-2 fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Type 2 diabetes mellitus
  • Phase I/II Constipation

Most Recent Events

  • 14 Apr 2018 Safety and efficacy data from a phase II trial in Non-alcoholic steatohepatitis released by NGM Bio
  • 14 Apr 2018 NGM Bio plans a phase IIb trial for Non-alcoholic steatohepatitis by the end of 2018
  • 13 Apr 2018 Safety, efficacy, and pharmacodynamic data from a phase II trial in Primary sclerosing cholangitis released by NGM Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top